Maintenance therapy with dose-adjusted 6-mercaptopurine in idiopathic pulmonary hemosiderosis

Pediatric Pulmonology

Volumn 43, Issue 11, 2008, Pages 1067-1071

  Luo, Xue Qun ^a   Ke, Zhi Yong ^a   Huang, Li Bin ^a   Guan, Xiao Qing ^a   Zhang, Xiao Li ^a   Jia, Zhu ^a   Zhang, Ying Chuang ^a  

^a THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Childhood; Diagnosis; Idiopathic pulmonary hemosiderosis; Treatment

Indexed keywords

MERCAPTOPURINE; PREDNISONE;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DISEASE COURSE; DRUG DOSE REDUCTION; FEMALE; HUMAN; IDIOPATHIC DISEASE; LEUKOCYTE COUNT; LEUKOPENIA; LUNG DISEASE; LUNG HEMOSIDEROSIS; MALE; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RELAPSE; REMISSION; TREATMENT OUTCOME;

6-MERCAPTOPURINE; ADOLESCENT; ANEMIA; ANTIMETABOLITES; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOSIDEROSIS; HUMANS; LUNG DISEASES; MALE;

EID: 57349172789     PISSN: 87556863     EISSN: 10990496     Source Type: Journal    
DOI: 10.1002/ppul.20894     Document Type: Article

References (23)

1. Blanco A, Solis P, Gomez S, Valbuena C, Telleria JJ. Antineutrophil cytoplasmic antibodies (ANCA) in idiopathic pulmonary hemosiderosis. Pediatr Allergy Immunol 1994;5:235-239.
2. Milman N, Pedersen M. Idiopathic pulmonary hemosiderosis. Epidemiology, pathogenic aspect and diagnosis. Respir Med 1998;92:902-907.
3. Kjellman B, Elinder G, Garwicz S, Svan H. Idiopathic pulmonary hemosiderosis in Swedish children. Acta Pediatr Scand 1984;73: 584-588.
4. Ohga S, Takahashi K, Miyazaki S, Kato H, Ueda K. Idiopathic pulmonary haemosiderosis in Japan: 39 possible cases from a survey questionnaire (letter). Eur J Pediatr 1995;154:994-995.
5. Saeed MM, Woo MS, Maclaughlin EP, Margetis MF, Keena TG. Prognosis in pediatric idiopathic pulmonary hemosiderosis. Chest 1999;116:721-725.
6. Yao TC, Hung IJ, Wong KS, Huang JL, Niu CK. Idiopathic pulmonary haemosiderosis: an oriental experience. J Paediatr Child Health 2003;9:27-30.
7. Kulkarni P. Cortez. Anemia. Clin Pediatr 2007;46:462-465.
8. Le Clainche L, Le Bourgeois M, Fauroux B, Forenza N, Dommergues JP, Desbois JC, Bellon G, Derelle J, Dutau G, Marguet C, Pin I, Tillie-Leblond I, Scheinmann P, de Blic J. Long-term outcome of idiopathic pulmonary hemosiderosis in children. Medicine 2000;79:318-326.
9. Kabra SK, Bhargava S, Lodha R, Satyavani A, Walia M. Idiopathic pulmonary hemosiderosis clinical profile and follow up of 26 children. Indian Pediatr 2007;44:333-338.
10. Kiper N, Gocmen A, Ozcelik U, Dilber E, Anadol D. Long-term clinical course of patients with idiopathic pulmonary hemosiderosis (1979-1994): prolonged survival with low-dose corticosteroid therapy. Pediatr Pulmonol 1999;27:180-184.
11. Chryssanthopoulos C, Cassimos C, Panagiotidou C. Prognostic criteria in idiopathic pulmonary hemosiderosis. Eur J Pediatr 1983;140:123-125.
12. Duley JA, Folrin THJ. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther Drug Monit 2005;27:647-654.
13. Mawatari H, Unei K, Nishimura SI, Sakura N, Ueda K. Comparative pharmacokinetics of oral 6-mercaptopuine and intravenous 6-mercaptopuine riboside in children. Pediatr Int 2001;43:673-677.
14. Ioachimescu OC, Sieber S, Kotch A. Idiopathic pulmonary haemosiderosis revisited. Eur Respir J 2004;24:162-169.
15. Tutor JD, Eid NS. Treatment of idiopathic pulmonary hemosiderosis with inhald flunisolide. South Med J 1995;88:984-986.
16. Cerati DE, Casar CE, Diaz CA. Idiopathic pulmonary hemosiderosis; long-term follow-up in 10 patients treated with corticoids and immunosuppressive agents. Bol Med Hosp Infant Mex 1980;37:985-1002.
17. Cuffari C, Theoret Y, Latour S, Seidman G. 6-mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996;39:401-406.
18. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, Seidman EG. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-713.
19. Pike MG, Franklin CL, Mays DC. Improved methods for determining the concentration of 6-thioguanine nucleotides and 6-methylmercaptopurine nucleotides in blood. J Chromatogr B 2001;757:1-9.
20. Lennard L, Rees CA, Lilleyman JS, Maddocks JL. Childhood leukemia: a relationship between intracellular 6-mercaptopurine metabolites and neutropenia. Br J Clin Pharmacol 1993; 16:359-363.
21. Dokmanovic U, Urosevic J, Janic D, Javanovic N, Petrucev B, Tosic N, Pavlovic S. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia. Ther Drug Monit 2006;28:800-806.
22. Chebli JMF, Gaburri PD, Souza AFMD, Pinto ALT, Chebli LA, Felga GEG, Forn CG, Pimentel CFMG. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. J Gastroenterol Hepatol 2007;22:268-274.
23. Achkar JP, Stevens T, Easley K, Brzezinski A, Seidner D. Indicators of clinical response to treatment with six-mercaptopurine or azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis 2004;10:339-345.